argenx SE (ARGX.BR)
EUR 575.6
(1.34%)
EUR 575.6
(1.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -272.91 Million EUR | 61.54% |
| 2022 | -709.59 Million USD | -73.81% |
| 2021 | -408.26 Million USD | 37.24% |
| 2020 | -650.54 Million EUR | -256.37% |
| 2019 | -182.54 Million EUR | -139.47% |
| 2018 | -76.23 Million EUR | -126.32% |
| 2017 | -33.68 Million EUR | -49.84% |
| 2016 | -22.47 Million EUR | -34.28% |
| 2015 | -16.74 Million EUR | -33.48% |
| 2014 | -12.54 Million EUR | -48.14% |
| 2013 | -8.46 Million EUR | 33.99% |
| 2012 | -12.82 Million EUR | -185.59% |
| 2011 | -4.49 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 29.06 Million EUR | 47.27% |
| 2024 Q1 | -61.59 Million USD | 37.98% |
| 2023 Q3 | -72.64 Million USD | 23.02% |
| 2023 Q1 | -28.87 Million USD | 25.23% |
| 2023 Q2 | -94.36 Million USD | -226.86% |
| 2023 FY | -272.91 Million EUR | 61.54% |
| 2023 Q4 | -99.17 Million USD | -36.52% |
| 2022 FY | -709.59 Million USD | -73.81% |
| 2022 Q3 | -235.04 Million USD | -12.6% |
| 2022 Q4 | -38.61 Million USD | 83.57% |
| 2022 Q1 | -227.18 Million USD | 4.47% |
| 2022 Q2 | -208.74 Million USD | 8.12% |
| 2021 Q1 | -40.43 Million EUR | 87.49% |
| 2021 FY | -408.26 Million USD | 37.24% |
| 2021 Q2 | 103.6 Million USD | 356.23% |
| 2021 Q3 | -233.61 Million USD | -325.5% |
| 2021 Q4 | -237.81 Million USD | -1.8% |
| 2020 Q4 | -323.28 Million EUR | 0.0% |
| 2020 FY | -650.54 Million EUR | -256.37% |
| 2020 Q2 | -205.63 Million EUR | 0.0% |
| 2019 Q1 | 7.57 Million EUR | 122.36% |
| 2019 FY | -182.54 Million EUR | -139.47% |
| 2019 Q4 | -92.9 Million EUR | -272.59% |
| 2019 Q3 | -24.93 Million EUR | 57.65% |
| 2019 Q2 | -58.88 Million EUR | -876.89% |
| 2018 Q2 | -1.44 Million EUR | 93.37% |
| 2018 Q3 | -19.12 Million EUR | -1224.58% |
| 2018 FY | -76.23 Million EUR | -126.32% |
| 2018 Q1 | -21.76 Million EUR | -51.72% |
| 2018 Q4 | -33.89 Million EUR | -77.2% |
| 2017 Q1 | -8.98 Million EUR | -7.25% |
| 2017 Q2 | -387.54 Thousand EUR | 95.69% |
| 2017 Q4 | -14.34 Million EUR | -44.05% |
| 2017 Q3 | -9.96 Million EUR | -2470.1% |
| 2017 FY | -33.68 Million EUR | -49.84% |
| 2016 Q3 | -5.91 Million EUR | -22.86% |
| 2016 Q1 | -3.36 Million EUR | 37.72% |
| 2016 FY | -22.47 Million EUR | -34.28% |
| 2016 Q2 | -4.81 Million EUR | -43.09% |
| 2016 Q4 | -8.37 Million EUR | -41.6% |
| 2015 Q2 | -4.64 Million EUR | -44.03% |
| 2015 FY | -16.74 Million EUR | -33.48% |
| 2015 Q4 | -5.4 Million EUR | -56.02% |
| 2015 Q3 | -3.46 Million EUR | 25.45% |
| 2015 Q1 | -3.22 Million EUR | 29.28% |
| 2014 Q2 | -3.67 Million EUR | -43.47% |
| 2014 Q3 | -1.74 Million EUR | 52.49% |
| 2014 Q4 | -4.56 Million EUR | -161.37% |
| 2014 FY | -12.54 Million EUR | -48.14% |
| 2014 Q1 | -2.56 Million EUR | -22.83% |
| 2013 Q2 | -3.95 Million EUR | -70.73% |
| 2013 Q3 | -102.69 Thousand EUR | 97.41% |
| 2013 Q4 | -2.08 Million EUR | -1930.17% |
| 2013 Q1 | -2.31 Million EUR | 0.0% |
| 2013 FY | -8.46 Million EUR | 33.99% |
| 2012 FY | -12.82 Million EUR | -185.59% |
| 2011 FY | -4.49 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nicox S.A. | -20.88 Million EUR | -1207.003% |
| European Medical Solutions | -709 Thousand EUR | -38392.992% |
| FERMENTALG | -14.14 Million EUR | -1829.003% |
| BioSenic S.A. | -28.77 Million EUR | -848.347% |
| Celyad Oncology SA | -8.44 Million EUR | -3130.532% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -1674.482% |
| Onward Medical N.V. | -36.18 Million EUR | -654.306% |
| Oxurion NV | -18.96 Million EUR | -1338.744% |
| PHAXIAM Therapeutics S.A. | -23.48 Million EUR | -1061.935% |
| Financière de Tubize SA | 88.15 Million EUR | 409.599% |
| UCB SA | 343 Million EUR | 179.567% |